Pre-hospital Antifibrinolytics For Traumatic Coagulopathy And Haemorrhage (The PATCH Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,668,152.00
Summary
About 2500 Australians die annually from severe injuries. Bleeding is exacerbated by early-onset clotting defects, which are associated with high mortality. The antifibrinolytic agent tranexamic acid has been shown to reduce mortality due to bleeding when given in hospital in less developed trauma systems, but its usefulness as a pre-emptive strike at the scene of injury in developed systems is unknown. Building on our prehospital clinical trials expertise, we will conduct a trial to assess its ....About 2500 Australians die annually from severe injuries. Bleeding is exacerbated by early-onset clotting defects, which are associated with high mortality. The antifibrinolytic agent tranexamic acid has been shown to reduce mortality due to bleeding when given in hospital in less developed trauma systems, but its usefulness as a pre-emptive strike at the scene of injury in developed systems is unknown. Building on our prehospital clinical trials expertise, we will conduct a trial to assess its effect on 6-month death and disability.Read moreRead less
STOP-AUST: The Spot Sign And Tranexamic Acid On Preventing Intracerebral Haemorrhage Growth – AUStralasia Trial
Funder
National Health and Medical Research Council
Funding Amount
$764,621.00
Summary
The STOP-AUST study is a randomized controlled trial with the aim of testing whether the medication tranexamic acid when given early within 4.5 hours of symptom onset is superior to standard care alone in stopping intracerebral haemorrhage (ICH, a bleeding into the brain) growth. Total 100 to 150 patients will be enrolled into the study.
REDucing Delays In Aneurysmal Subarachnoid Haemorrhage: The REDDISH Study
Funder
National Health and Medical Research Council
Funding Amount
$436,022.00
Summary
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare form of stroke that kills at least 30% of sufferers within 1 month. Outcome can be improved through quickly receiving medical care but many people do not and this likely contributes to the poor outcomes. The REDucing Delays In Subarachnoid Haemorrhage (REDDISH) study will look at cases of aSAH across Tasmanian and Victoria so that we can understand the factors that contribute to delays in treatment and ultimately improve outcomes.
Enhanced Control Of Hypertension And Thrombolysis In Stroke Study (STAY ENCHANTED)
Funder
National Health and Medical Research Council
Funding Amount
$2,437,384.00
Summary
"Clot busting" treatment is the only approved medical treatment for the commonest type of stroke, ischaemic stroke. However, uptake of treatment remains poor, mainly due to the known major risk of bleeding in the brain. STAY ENCHANTED is an international clinical trial to investigate whether "clot-busting" can be made safer using a lower dose and/or immediate blood pressure lowering. A safer more effective regime could have a major global health impact.
Patterns Of Care And Outcomes For Subarachnoid Haemorrhage: A Data Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$125,625.00
Summary
As many as 30% of people with subarachnoid haemorrahge (SAH) die within 90 days. Survivors are often left disabled. Death rates appear to be decreasing. Identifying health service variables that impact positively on survival has the potential to inform health policy and practice. We will describe variations in mortality, hospital re-admission and patterns of care. The study will observe the uptake of new SAH management including new neurosurgical techniques.
The Effect Of Anti-fibrinolytic Drugs On Blood-brain Barrier Integrity And The Immune Response In Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$870,476.00
Summary
This project aims to determine how a well known anti-fibrinolytic drug can improve the immune response and reduced blood brain barrier disruption following traumatic brain injury. We will also be testing additional drugs we have developed as well as a novel drug delivery system that better targets drugs to the damaged brain.